Nymox Pharmaceutical Corporation’s shares were up 35.2% after the company announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on its lead candidate, fexapotide (NX-1207).

The study evaluated fexapotide, in comparison to placebo, in men (n=995) with prostate enlargement (benign prostate hyperplasia/BPH) symptoms. Subjects were evaluated thoroughly to exclude any prostate cancer prior to treatment with fexapotide. They were followed for up to seven years (median of five years) after treatment.

Data from the study demonstrated that men receiving fexapotide revealed a major reduction in the incidence of prostate cancer, compared to placebo, as well as to the known and expected normal incidence of the disease. Data also revealed a statistically significant and very low incidence of 1.3% for prostate cancer.

We note that Nymox is developing fexapotide in a phase III study for the treatment of BPH and in a phase II study for the treatment of low-grade localized prostate cancer.

We remind investors that earlier this year, the company has announced results from a phase II study – NX03-0040 – on fexapotide for the treatment of localized prostate cancer. The study met its pre-determined endpoints. There was a significant improvement in cancer progression outcomes in the fexapotide-treated patient groups.

Stocks to Consider:

Investors interested in the health care sector may consider stocks such as Pfizer Inc. (PFE Quick QuotePFE - Free Report) , ANI Pharmaceuticals, Inc. (ANIP Quick QuoteANIP - Free Report) and Retrophin, Inc. . All these stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>